Cargando…

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis

BACKGROUND: BRAF gene mutation causes melanoma patients to develop drug resistance after 8–9 months BRAF inhibitors treatment. Therefore, overcoming BRAF inhibitor resistance has important implications for improving patient survival. Sorafenib directly inhibits tumor cell proliferation by blocking t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Fengjie, Li, Shiyan, Liu, Daisong, Chen, Jian, Han, Chaofei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798636/ https://www.ncbi.nlm.nih.gov/pubmed/35117506 http://dx.doi.org/10.21037/tcr.2020.01.62

Ejemplares similares

Silencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis
por: Liu, Can, et al.
Publicado: (2020)

Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma: The role of Arginase 2 in sorafenib-induced ferroptosis in melanoma
por: Yu, Yi, et al.
Publicado: (2022)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
por: Guzzetti, Carlotta, et al.
Publicado: (2023)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Galectin-3 sensitized melanoma cell lines to vemurafenib (PLX4032) induced cell death through prevention of autophagy
por: Bustos, Silvina Odete, et al.
Publicado: (2018)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts
por: Lee, Woan-Ruoh, et al.
Publicado: (2015)

RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
por: Zhao, Kun, et al.
Publicado: (2020)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
por: Hernandez-Davies, Jenny E, et al.
Publicado: (2015)

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
por: Tan, Yufan, et al.
Publicado: (2021)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells
por: Li, Hongmin, et al.
Publicado: (2023)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells
por: Bokharaie, Honey, et al.
Publicado: (2022)

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells
por: Tabolacci, Claudio, et al.
Publicado: (2022)

3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells
por: Vital, Patrik da Silva, et al.
Publicado: (2022)

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis
por: Li, Yan, et al.
Publicado: (2023)

Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3
por: Hu, Zongqiang, et al.
Publicado: (2023)

Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2
por: Elkateb, Ahmed S., et al.
Publicado: (2023)

Quaternized chitosan promotes the antiproliferative effect of vemurafenib in melanoma cells by increasing cell permeability
por: Li, Min, et al.
Publicado: (2018)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
por: Castellani, Elisa, et al.
Publicado: (2012)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas
por: Liu, Fang, et al.
Publicado: (2013)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
por: Goodall, Megan L, et al.
Publicado: (2014)

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
por: Faião-Flores, F, et al.
Publicado: (2017)

Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics
por: Grahovac, Jelena, et al.
Publicado: (2019)

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
por: Salton, Maayan, et al.
Publicado: (2015)

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
por: Wolf, Sanne EJ, et al.
Publicado: (2013)

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
por: de Haan, Jorine, et al.
Publicado: (2018)

Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib
por: Rajczykowski, Marcin, et al.
Publicado: (2018)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
por: Radi, Rakan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_edrr8tgpv168uh30mi7fllsfk5